title: A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor.
authors.affiliation: The Kellgren Centre for Rheumatology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester.
authors.forename: Surabhi
authors.initials: S
authors.lastname: Wig
authors.affiliation: Department of Rheumatology, Countess of Chester Hospital NHS Foundation Trust, Chester.
authors.forename: Marian
authors.initials: M
authors.lastname: Chan
authors.affiliation: Department of Haematology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary.
authors.forename: Jecko
authors.initials: J
authors.lastname: Thachil
authors.affiliation: The Kellgren Centre for Rheumatology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Bruce
authors.affiliation: Department of Rheumatology, Countess of Chester Hospital NHS Foundation Trust, Chester.
authors.forename: Theresa
authors.initials: T
authors.lastname: Barnes
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects; D003182:Complement C5 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D006801:Humans; D012008:Recurrence; D012720:Severity of Illness Index
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; C481642:eculizumab